Literature DB >> 18237252

Tumor markers in staging and prognosis of colorectal carcinoma.

M Levy1, V Visokai, L Lipska, O Topolcan.   

Abstract

The precise preoperative staging of colorectal cancer is fundamental for surgical strategy, incomplete staging means incomplete treatment and poor outcome. Large-scale clinical evaluations of predictive markers are currently in progress, including determination of their ability to predict response of patients to therapy for advanced disease and for adjuvant treatment. Lack of specificity and sensitivity preclude the use of all existing serum markers for the early detection of colorectal carcinoma. The aim of the study was to investigate the clinical significance of serum tumor markers and biological activity markers -- oncofetal tumormarker CEA, mucin tumormarkers CA19-9, CA242, proliferative tumor markers Thymidine kinase, soluble cytoceratines fragments TPS, TPA, adhesive molecules ICAM - 1, VCAM -1, IGF-1, and adipocytokinins Adiponectin, Leptin in patients with colorectal cancer before primary operation. The study included 142 patients between the ages of 35 - 89 years. Operated between November 2003 to March 2006. We have confirmed that CA19-9 is besides CEA an important marker in colorectal cancer. Comparing CA19-9 and CA242 in preoperative staging, CA242 is more specific. Statistical significant difference between early and metastatic stage of colorectal cancer was not confirmed in markers: ICAM-1, VCAM, adiponectin, leptin. Statistical significant difference between early and metastatic stage of colorectal cancer was confirmed in markers: CEA, CA19-9, CA242, TPS, TPA, TK, IGF-1. None of the used markers was able to distinguish stage II and III, in other words to identify patients with infiltration of lymph nodes. This fact is very important in our aspirations to find which marker from periferal blood could help to poit out patients in risk of lymphatic infiltration and to indicate these patients for adjuvant therapy. Combination of CEA and either CA19-9 or CA242 can be recommended for preoperative investigation. CA 242 in this study seems to have slightly better results in preoperative staging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237252

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  21 in total

1.  Identification of phospholipid scramblase 1 as a biomarker and determination of its prognostic value for colorectal cancer.

Authors:  Yung-Bin Kuo; Chung-Chuan Chan; C Allen Chang; Chung-Wei Fan; Ray-Ping Hung; Ya-Shu Hung; Kuei-Tien Chen; Jau-Song Yu; Yu-Sun Chang; Err-Cheng Chan
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma.

Authors:  Jian-hua Cai; Ren Zhao; Jian-wei Zhu; Xiao-long Jin; Fang-jun Wan; Kun Liu; Xiao-pin Ji; Yan-bo Zhu; Zheng-gang Zhu
Journal:  J Gastrointest Surg       Date:  2010-06-08       Impact factor: 3.452

3.  Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.

Authors:  Xue-Qin Yang; Chuang Chen; Chun-Wei Peng; Shao-Ping Liu; Yan Li
Journal:  Med Oncol       Date:  2011-05-07       Impact factor: 3.064

4.  Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

Authors:  Yifan Peng; Zhiwei Zhai; Zhongmin Li; Lin Wang; Jin Gu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 5.  Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.

Authors:  Chiara De Divitiis; Guglielmo Nasti; Massimo Montano; Rossella Fisichella; Rosario Vincenzo Iaffaioli; Massimiliano Berretta
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 6.  Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Authors:  Gustaw Lech; Robert Słotwiński; Maciej Słodkowski; Ireneusz Wojciech Krasnodębski
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

7.  Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer.

Authors:  Sayaka Otake; Hiroaki Takeda; Shoichiro Fujishima; Tadahisa Fukui; Tomohiko Orii; Takeshi Sato; Yu Sasaki; Shoichi Nishise; Sumio Kawata
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

8.  Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer.

Authors:  E Polat; U Duman; M Duman; A E Atici; E Reyhan; T Dalgic; E B Bostanci; S Yol
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

9.  Growth and invasion of sporadic colorectal adenocarcinomas in terms of genetic change.

Authors:  Seon Ae Roh; Eun Young Choi; Dong Hyung Cho; Se Jin Jang; Seon Young Kim; Yong Sung Kim; Jin Cheon Kim
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

10.  Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.

Authors:  Anna Kumor; Piotr Daniel; Mirosława Pietruczuk; Ewa Małecka-Panas
Journal:  Int J Colorectal Dis       Date:  2008-11-01       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.